Caribou Biosciences, Inc.

Caribou Biosciences, Inc. (CRBU) priced its initial public offering on Jul 23, 2021 at $16.00 per share, within its $14.00–$16.00 range, raising $304M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $907.3M. BofA Securities was lead-left underwriter, joined by Citigroup and Leerink Partners. Reed Smith advised the company and A&O Shearman advised the underwriters.

Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company developing genome-edited cell therapies using its chRDNA CRISPR platform. The company says the technology enables multiple precise genomic edits while preserving genomic integrity.

Status

IPO

Ticker

CRBU

Exchange

Nasdaq Global Select

Priced

Jul 23, 2021

IPO price

$16.00

Price range

$14.00–$16.00

Raised

$304M

Market cap at IPO price

$907.3M

First filed

Jul 1, 2021

Underwriters

BofA Securities, Citigroup and Leerink Partners

Company counsel

Reed Smith

Underwriters' counsel

A&O Shearman

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.